Peptide vaccine: Progress and challenges

Vaccines

Volumn 2, Issue 3, 2014, Pages 515-536

  Li, Weidang ^a   Joshi, Medha D ^b   Singhania, Smita ^c   Ramsey, Kyle H ^a   Murthy, Ashlesh K ^a  

^a MIDWESTERN UNIVERSITY   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c SYMBIOSIS INTERNATIONAL DEEMED UNIVERSITY   (India)

Author keywords

Adjuvants; Epitope; Peptide vaccine

Indexed keywords

AS02; AS03; CARBON NANOTUBE; DENDRIMER; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; GOLD NANOPARTICLE; GONADORELIN; HEPATITIS A VACCINE; IMMUNOGLOBULIN A; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; ISCOM; ISCOMATRIX; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MIFAMURTIDE; MONTANIDE; MPL1; MUCIN 1; NANOCARRIER; NIOSOME; NUCLEOCAPSID PROTEIN; OLIGODEOXYNUCLEOTIDE; OVALBUMIN; PEPTIDE VACCINE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; UNCLASSIFIED DRUG; VIROSOME; WART VIRUS VACCINE;

ACTIVE IMMUNIZATION; ACUTE TOXICITY; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EMULSION; HELPER CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MEMBRANE MICROPARTICLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; REVIEW; SARS CORONAVIRUS; X RAY CRYSTALLOGRAPHY;

EID: 85019447249     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2030515     Document Type: Review

References (117)

1. Bachler, B.C.; Humbert, M.; Palikuqi, B.; Siddappa, N.B.; Lakhashe, S.K.; Rasmussen, R.A.; Ruprecht, R.M. Novel biopanning strategy to identify epitopes associated with vaccine protection. J. Virol. 2013, 87, 4403-4416.
2. Perrie, Y.; Kirby, D.; Bramwell, V.W.; Mohammed, A.R. Recent developments in particulate-based vaccines. Recent Pat. Drug Deliv. Formul. 2007, 1, 117-129.
3. Black, M.; Trent, A.; Tirrell, M.; Olive, C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev. Vaccines 2010, 9, 157-173.
4. Thompson, A.L.; Staats, H.F. Cytokines: The future of intranasal vaccine adjuvants. Clin. Dev. Immunol. 2011, 2011, doi:10.1155/2011/289597.
5. Petrovsky, N.; Aguilar, J.C. Vaccine adjuvants: Current state and future trends. Immunol. Cell Biol. 2004, 82, 488-496.
6. Sesardic, D. Synthetic peptide vaccines. J. Med. Microbiol. 1993, 39, 241-242.
7. Bijker, M.S.; Melief, C.J.; Offringa, R.; van der Burg, S.H. Design and development of synthetic peptide vaccines: Past, present and future. Expert Rev. Vaccines 2007, 6, 591-603.
8. Lin, S.Y.; Cheng, C.W.; Su, E.C. Prediction of B-cell epitopes using evolutionary information and propensity scales. BMC Bioinform. 2013, 14, doi:10.1186/1471-2105-14-S2-S10.
9. Purcell, A.W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6, 404-414.
10. Aguilar, J.C.; Rodriguez, E.G. Vaccine adjuvants revisited. Vaccine 2007, 25, 3752-3762.
11. Liu, Y.; McNevin, J.; Zhao, H.; Tebit, D.M.; Troyer, R.M.; McSweyn, M.; Ghosh, A.K.; Shriner, D.; Arts, E.J.; McElrath, M.J.; et al. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: Fitness-balanced escape. J. Virol. 2007, 81, 12179-12188.
12. Kolesanova, E.F.; Sanzhakov, M.A.; Kharybin, O.N. Development of the schedule for multiple parallel "difficult" Peptide synthesis on pins. Int. J. Pept. 2013, 2013, doi:10.1155/2013/197317.
13. Epstein, J.E.; Giersing, B.; Mullen, G.; Moorthy, V.; Richie, T.L. Malaria vaccines: Are we getting closer? Curr. Opin. Mol. Ther. 2007, 9, 12-24.
14. Volpina, O.M.; Gelfanov, V.M.; Yarov, A.V.; Surovoy, A.Y.; Chepurkin, A.V.; Ivanov, V.T. New virus-specific T-helper epitopes of foot-and-mouth disease viral VP1 protein. FEBS Lett. 1993, 333, 175-178.
15. Tarradas, J.; Monso, M.; Munoz, M.; Rosell, R.; Fraile, L.; Frías, M.T.; Domingo, M.; Andreu, D.; Sobrino, F.; Ganges, L. Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs. Vaccine 2011, 29, 4422-4429.
16. Stanekova, Z.; Kiraly, J.; Stropkovska, A.; Mikušková, T.; Mucha, V.; Kostolanský, F.; Varečková, E. Heterosubtypic protective immunity against influenza a virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol. 2011, 55, 61-67.
17. Oscherwitz, J.; Yu, F.; Cease, K.B. A synthetic peptide vaccine directed against the 2ss2-2ss3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. J. Immunol. 2010, 185, 3661-3668.
18. Solares, A.M.; Baladron, I.; Ramos, T.; Valenzuela, C.; Borbon, Z.; Fanjull, S.; Gonzalez, L.; Castillo, D.; Esmir, J.; Granadillo, M.; et al. Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human, proof-of-concept trial. ISRN Obstet. Gynecol. 2011, 2011, doi:10.5402/2011/292951.
19. Bernhardt, S.L.; Gjertsen, M.K.; Trachsel, S.; Møller, M.; Eriksen, J.A.; Meo, M.; Buanes, T.; Gaudernack, G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br. J. Cancer 2006, 95, 1474-1482.
20. Brunsvig, P.F.; Aamdal, S.; Gjertsen, M.K.; Kvalheim, G.; Markowski-Grimsrud, C.J.; Sve, I.; Dyrhaug, M.; Trachsel, S.; Møller, M.; Eriksen, J.A.; et al. Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006, 55, 1553-1564.
21. Brunsvig, P.F.; Kyte, J.A.; Kersten, C.; Sundstrøm, S.; Møller, M.; Nyakas, M.; Hansen, G.L.; Gaudernack, G.; Aamdal, S. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. 2011, 17, 6847-6857.
22. Kyte, J.A.; Gaudernack, G.; Dueland, S.; Trachsel, S.; Julsrud, L.; Aamdal, S. Telomerase peptide vaccination combined with temozolomide: A clinical trial in stage IV melanoma patients. Clin. Cancer Res. 2011, 17, 4568-4580.
23. Greten, T.F.; Forner, A.; Korangy, F.; N'Kontchou, G.; Barget, N.; Ayuso, C.; Ormandy, L.A.; Manns, M.P.; Beaugrand, M.; Bruix, J. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010, 10, e209.
24. Kyte, J.A.; Trachsel, S.; Risberg, B.; Thor, S.P.; Lislerud, K.; Gaudernack, G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol. Immunother. 2009, 58, 1609-1626.
25. Demento, S.L.; Siefert, A.L.; Bandyopadhyay, A.; Sharp, F.A.; Fahmy, T.M. Pathogen-associated molecular patterns on biomaterials: A paradigm for engineering new vaccines. Trends Biotechnol. 2011, 29, 294-306.
26. Burioni, R.; Perotti, M.; Mancini, N.; Clementi, M. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J. Hepatol. 2008, 49, 299-300.
27. Testa, J.S.; Philip, R. Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol. 2012, 7, 1077-1088.
28. Lanier, J.G.; Newman, M.J.; Lee, E.M.; Sette, A.; Ahmed, R. Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses. Vaccine 1999, 18, 549-557.
29. Corti, D.; Voss, J.; Gamblin, S.J.; Codoni, G.; Macagno, A.; Jarrossay, D.; Vachieri, S.G.; Pinna, D.; Minola, A.; Vanzetta, F.; et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333, 850-856.
30. Hager-Braun, C.; Tomer, K.B. Determination of protein-derived epitopes by mass spectrometry. Expert Rev. Proteomics 2005, 2, 745-756.
31. Panina-Bordignon, P.; Demotz, S.; Corradin, G.; Lanzavecchia, A. Study on the immunogenicity of human class-II-restricted T-cell epitopes: Processing constraints, degenerate binding, and promiscuous recognition. Cold Spring Harb. Symp. Quant. Biol. 1989, 54, 445-451.
32. Huang, J.; Ru, B.; Zhu, P.; Nie, F.; Yang, J.; Wang, X.; Dai, P.; Lin, H.; Guo, F.B.; Rao, N. MimoDB 2.0: A mimotope database and beyond. Nucleic Acids Res. 2012, 40, D271-D277.
33. Gershoni, J.M.; Roitburd-Berman, A.; Siman-Tov, D.D.; Tarnovitski, F.N.; Weiss, Y. Epitope mapping: The first step in developing epitope-based vaccines. BioDrugs 2007, 21, 145-156.
34. Langeveld, J.P.; Casal, J.I.; Osterhaus, A.D.; Cortés, E.; de Swart, R.; Vela, C.; Dalsgaard, K.; Puijk, W.C.; Schaaper, W.M.; Meloen, R.H. First peptdie vaccine providing protection against viral infection in the target animal; studies of canine parvovirus in dogs. J. Virol. 1994, 68, 4506-4513.
35. Kupriianova, M.A.; Zhmak, M.N.; Koroev, D.O.; Chepurkin, A.V.; Vol'pina, O.M.; Ivanov, V.T. Synthetic peptide designs based on immunoactive fragments of the VP1 protein of the foot-and-mouth disease virus strain A22. Bioorg. Khimiia 2000, 26, 926-932.
36. Robinson, J.; Waller, M.J.; Fail, S.C.; Mcwilliam, H.; Lopez, R.; Parham, P.; Marsh, S.G.E. The IMGT/HLA database. Nucleic Acids Res. 2009, 37, D1013-D1017.
37. Schuler, M.M.; Nastke, M.D.; Stevanovikc, S. SYFPEITHI: Database for searching and T-cell epitope prediction. Methods Mol. Biol. 2007, 409, 75-93.
38. Michielin, O.; Luescher, I.; Karplus, M. Modeling of the TCR-MHC-peptide complex. J. Mol. Biol. 2000, 300, 1205-1235.
39. Lin, H.H.; Ray, S.; Tongchusak, S.; Reinherz, E.L.; Brusic, V. Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research. BMC Immunol. 2008, 9, doi:10.1186/1471-2172-9-8.
40. Townsend, A.R.; Rothbard, J.; Gotch, F.M.; Bahadur, G.; Wraith, D.; McMichael, A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986, 44, 959-968.
41. Townsend, A.R.; McMichael, A.J. Specificity of cytotoxic T lymphocytes stimulated with influenza virus. Studies in mice and humans. Prog. Allergy 1985, 36, 10-43.
42. Townsend, A.R.; Skehel, J.J.; Taylor, P.M.; Palese, P. Recognition of influenza A virus nucleoprotein by an H-2-restricted cytotoxic T-cell clone. Virology 1984, 133, 456-459.
43. Aichele, P.; Brduscha-Riem, K.; Zinkernagel, R.M.; Hengartner, H.; Pircher, H. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 1995, 182, 261-266.
44. Aichele, P.; Hengartner, H.; Zinkernagel, R.M.; Schulz, M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 1990, 171, 1815-1820.
45. Azizi, A.; Anderson, D.E.; Torres, J.V.; Ogrel, A.; Ghorbani, M.; Soare, C.; Sandstrom, P.; Fournier, J.; Diaz-Mitoma, F. Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J. Immunol. 2008, 180, 2174-2186.
46. Kast, W.M.; Roux, L.; Curren, J.; Blom, H.J.; Voordouw, A.C.; Meloen, R.H.; Kolakofsky, D.; Melief, C.J. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 1991, 88, 2283-2287.
47. Wahala, W.M.; Silva, A.M. The human antibody response to dengue virus infection. Viruses 2011, 3, 2374-2395.
48. Joshi, M.D.; Unger, W.J.; Storm, G.; van, K.Y.; Mastrobattista, E. Targeting tumor antigens to dendritic cells using particulate carriers. J. Control Release 2012, 161, 25-37.
49. Xu, Z.; Ramishetti, S.; Tseng, Y.C.; Guo, S.; Wang, Y.; Huang, L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J. Control Release 2013, 172, 259-265.
50. Quakkelaar, E.D.; Melief, C.J. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv. Immunol. 2012, 114, 77-106.
51. Quakkelaar, E.D.; Bunnik, E.M.; van Alphen, F.P.; Boeser-Nunnink, B.D.; van Nuenen, A.C.; Schuitemaker, H. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. Virology 2007, 363, 447-453.
52. Moisa, A.A.; Kolesanova, E.F. Synthetic peptide vaccines. Biomed. Khimiia 2011, 57, 14-30.
53. Fayolle, C.; del-Motal, U.M.; Berg, L.; Deriaud, E.; Jondal, M.; Leclerc, C. Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help. Immunology 1996, 89, 41-45.
54. Fayolle, C.; Sebo, P.; Ladant, D.; Ullmann, A.; Leclerc, C. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J. Immunol. 1996, 156, 4697-4706.
55. Zwaveling, S.; Ferreira Mota, S.C.; Nouta, J.; Johnson, M.; Lipford, G.B.; Offringa, R.; van der Burg, S.H.; Melief, C.J. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 2002, 169, 350-358.
56. Welters, M.J.; Kenter, G.G.; Piersma, S.J.; Vloon, A.P.; Löwik, M.J.; Berends-van der Meer, D.M.; Drijfhout, J.W.; Valentijn, A.R.; Wafelman, A.R.; Oostendorp, J.; et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 2008, 14, 178-187.
57. Welters, M.J.; van der, L.P.; van den Eeden, S.J.; Kwappenberg, K.M.C.; Drijfhout, J.W.; Fleuren, G.J.; Kenter, G.G.; Melief, C.J.M.; van der Burg, S.H.; Offringa, R. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int. J. Cancer 2006, 118, 950-956.
58. Welters, M.J.; Kenter, G.G.; de Vos van Steenwijk, P.J.; Löwik, M.J.; Berends-van der Meer, D.M.; Essahsah, F.; Stynenbosch, L.F.; Vloon, A.P.; Ramwadhdoebe, T.H.; Piersma, S.J.; et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. USA 2010, 107, 11895-11899.
59. Panina-Bordignon, P.; Tan, A.; Termijtelen, A.; Demotz, S.; Corradin, G.; Lanzavecchia, A. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 1989, 19, 2237-2242.
60. Agadjanyan, M.G.; Ghochikyan, A.; Petrushina, I.; Vasilevko, V.; Movsesyan, N.; Mkrtichyan, M.; Saing, T.; Cribbs, D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 2005, 174, 1580-1586.
61. Chen, W.; Ede, N.J.; Jackson, D.C.; McCluskey, J.; Purcell, A.W. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J. Immunol. 1996, 157, 1000-1005.
62. Jackson, D.C.; Purcell, A.W.; Fitzmaurice, C.J.; Zeng, W.; Hart, D.N. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr. Drug Targets 2002, 3, 175-196.
63. Koh, Y.T.; Higgins, S.A.; Weber, J.S.; Kast, W.M. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J. Transl. Med. 2006, 4, doi:10.1186/1479-5876-4-42.
64. Kalariya, M.; Ganta, S.; Amiji, M. Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy. Pharm. Res. 2012, 29, 3393-3403.
65. Chen, Y.F.; Lin, C.W.; Tsao, Y.P.; Chen, S.L. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J. Virol. 2004, 78, 1333-1343.
66. Van Driel, W.J.; Ressing, M.E.; Kenter, G.G.; Brandt, R.M.; Krul, E.J.; van Rossum, A.B.; Schuuring, E.; Offringa, R.; Bauknecht, T.; Tamm-Hermelink, A.; et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial. Eur. J. Cancer 1999, 35, 946-952.
67. Slingluff, C.L., Jr.; Petroni, G.R.; Yamshchikov, G.V.; Barnd, D.L.; Eastham, S.; Galavotti, H.; Patterson, J.W.; Deacon, D.H.; Hibbitts, S.; Teates, D.; et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 2003, 21, 4016-4026.
68. Pinder, M.; Reece, W.H.; Plebanski, M.; Akinwunmi, P.; Flanagan, K.L.; Lee, E.A.; Doherty, T.; Milligan, P.; Jaye, A.; Tornieporth, N.; et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS, S/AS02, in semi-immune adults in The Gambia. Clin. Exp. Immunol. 2004, 135, 286-293.
69. Beebe, M.; Qin, M.; Moi, M.; Wu, S.; Heiati, H.; Walker, L.; Newman, M.; Fikes, J.; Ishioka, G.Y. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Hum. Vaccines 2008, 4, 210-218.
70. Iseki, K.; Matsunaga, H.; Komatsu, N.; Suekane, S.; Noguchi, M.; Itoh, K.; Yamada, A. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Sci. 2010, 101, 2110-2114.
71. Liang, M.T.; Davies, N.M.; Blanchfield, J.T.; Toth, I. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr. Drug Deliv. 2006, 3, 379-388.
72. Nagata, T.; Toyota, T.; Ishigaki, H.; Ichihashi, T.; Kajino, K.; Kashima, Y.; Itoh, Y.; Mori, M.; Oda, H.; Yamamura, H.; et al. Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. Vaccine 2007, 25, 4914-4921.
73. Taneichi, M.; Tanaka, Y.; Kakiuchi, T.; Uchida, T. Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS One 2010, 5, e15091.
74. Kohyama, S.; Ohno, S.; Suda, T.; Taneichi, M.; Yokoyama, S.; Mori, M.; Kobayashi, A.; Hayashi, H.; Uchida, T.; Matsui, M. Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. Antivir. Res. 2009, 84, 168-177.
75. Takagi, A.; Matsui, M.; Ohno, S.; Duan, H.; Moriya, O.; Kobayashi, N.; Oda, H.; Mori, M.; Kobayashi, A.; Taneichi, M.; et al. Highly efficient antiviral CD8+ T-cell induction by peptides coupled to the surfaces of liposomes. Clin. Vaccine Immunol. 2009, 16, 1383-1392.
76. Guan, H.H.; Budzynski, W.; Koganty, R.R.; Krantz, M.J.; Reddish, M.A.; Rogers, J.A.; Longenecker, B.M.; Samuel, J. Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses. Bioconjug. Chem. 1998, 9, 451-458.
77. Cortesi, R.; Argnani, R.; Esposito, E.; Dalpiaz, A.; Scatturin, A.; Bortolotti, F.; Lufino, M.; Guerrini, R.; Cavicchioni, G.; Incorvaia, C.; et al. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int. J. Pharm. 2006, 317, 90-100.
78. Henriksen-Lacey, M.; Korsholm, K.S.; Andersen, P.; Perrie, Y.; Christensen, D. Liposomal vaccine delivery systems. Expert Opin. Drug Deliv. 2011, 8, 505-519.
79. Sugita, T.; Yoshikawa, T.; Gao, J.Q.; Shimokawa, M.; Oda, A.; Niwa, T.; Akashi, M.; Tsutsumi, Y.; Mayumi, T.; Nakagawa, S. Fusogenic liposome can be used as an effective vaccine carrier for peptide vaccination to induce cytotoxic T lymphocyte (CTL) response. Biol. Pharm. Bull. 2005, 28, 192-193.
80. Chang, J.S.; Choi, M.J.; Cheong, H.S.; Kim, K. Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine 2001, 19, 3608-3614.
81. Chang, J.S.; Choi, M.J.; Kim, T.Y.; Cho, S.Y.; Cheong, H.S. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes. Vaccine 1999, 17, 1540-1548.
82. Hayashi, A.; Wakita, H.; Yoshikawa, T.; Nakanishi, T.; Tsutsumi, Y.; Mayumie, T.; Mukai, Y.; Yoshioka, Y.; Okada, N.; Nakagawa, S.; et al. A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity. J. Control Release 2007, 117, 11-19.
83. Awate, S.; Babiuk, L.A.; Mutwiri, G. Mechanisms of action of adjuvants. Front. Immunol. 2013, 4, doi:10.3389/fimmu.2013.00114.
84. Okitsu, S.L.; Boato, F.; Mueller, M.S.; Li, D.B.; Vogel, D.; Westerfeld, N.; Zurbriggen, R.; Robinson, J.A.; Pluschke, G. Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites. Peptides 2007, 28, 2051-2060.
85. Cryz, S.J.; Que, J.U.; Gluck, R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 1996, 14, 1381-1383.
86. Westerfeld, N.; Pluschke, G.; Zurbriggen, R. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes. Wien. klinische Wochenschr. 2006, 118, 50-57.
87. Herzog, C.; Hartmann, K.; Kunzi, V.; Kürsteiner, O.; Mischler, R.; Lazar, H.; Glück, R. Eleven years of inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27, 4381-4387.
88. Sun, H.X.; Xie, Y.; Ye, Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27, 4388-4401.
89. Morelli, A.B.; Becher, D.; Koernig, S.; Silva, A.; Drane, D.; Maraskovsky, E. ISCOMATRIX: A novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J. Med. Microbiol. 2012, 61, 935-943.
90. Duewell, P.; Kisser, U.; Heckelsmiller, K.; Hoves, S.; Stoitzner, P.; Koernig, S.; Morelli, A.B.; Clausen, B.E.; Dauer, M.; Eigler, A.; et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J. Immunol. 2011, 187, 55-63.
91. Agrawal, L.; Haq, W.; Hanson, C.V.; Rao, D.N. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity. J. Immune Based Ther. Vaccines 2003, 1, doi:10.1186/1476-8518-1-5.
92. Reed, S.G.; Orr, M.T.; Fox, C.B. Key roles of adjuvants in modern vaccines. Nat. Med. 2013, 19, 1597-1608.
93. Kang, N.; Perron, M.E.; Prud'homme, R.E.; Zhang, Y.; Gaucher, G.; Leroux, J.C. Stereocomplex block copolymer micelles: Core-shell nanostructures with enhanced stability. Nano Lett. 2005, 5, 315-319.
94. Correia-Pinto, J.F.; Csaba, N.; Alonso, M.J. Vaccine delivery carriers: Insights and future perspectives. Int. J. Pharm. 2013, 440, 27-38.
95. Buyuktimkin, B.; Wang, Q.; Kiptoo, P.; Stewart, J.M.; Berkland, C.; Siahaan, T.J. Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis. Mol. Pharm. 2012, 9, 979-985.
96. Heffernan, M.J.; Zaharoff, D.A.; Fallon, J.K.; Schlom, J.; Greiner, J.W. In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 2011, 32, 926-932.
97. Saenz, L.; Neira-Carrillo, A.; Paredes, R.; Cortes, M.; Bucarey, S.; Arias, J.L. Chitosan formulations improve the immunogenicity of a GnRH-I peptide-based vaccine. Int. J. Pharm. 2009, 369, 64-71.
98. Zaharoff, D.A.; Rogers, C.J.; Hance, K.W.; Schlom, J.; Greiner, J.W. Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine 2007, 25, 8673-8686.
99. Chua, B.Y.; Al, K.M.; Zeng, W.; Mainwaring, D.; Jackson, D.C. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol. Pharm. 2012, 9, 81-90.
100. Gaertner, H.F.; Cerini, F.; Kamath, A.; Rochat, A.-F.; Siegrist, C.-A.; Menin, L.; Hartley, O. Efficient orthogonal bioconjugation of dendrimers for synthesis of bioactive nanoparticles. Bioconjug. Chem. 2011, 22, 1103-1114.
101. Chen, Y.S.; Hung, Y.C.; Lin, L.W.; Liau, I.; Hong, M.Y.; Huang, G.S. Size-dependent impairment of cognition in mice caused by the injection of gold nanoparticles. Nanotechnology 2010, 21, doi:10.1088/0957-4484/21/48/485102.
102. Jalali, S.A.; Sankian, M.; Tavakkol-Afshari, J.; Jaafari, M.R. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomedicine 2012, 8, 692-701.
103. Daftarian, P.; Mansour, M.; Benoit, A.C.; Pohajdak, B.; Hoskin, D.W.; Brown, R.G.; Kast, W.M. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006, 24, 5235-5244.
104. Jiang, T.; Singh, B.; Li, H.S.; Kim, Y.K.; Kang, S.K.; Nah, J.W.; Choi, Y.J.; Cho, C.S. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 2014, 35, 2365-2373.
105. Fischer, S.; Schlosser, E.; Mueller, M.; Csaba, N.; Merkle, H.P.; Groettrup, M.; Gander, B. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J. Drug Target. 2009, 17, 652-661.
106. Garlapati, S.; Garg, R.; Brownlie, R.; Latimer, L.; Simko, E.; Hancock, R.E.; Babiuk, L.A.; Gerdts, V.; Potter, A.; van Drunen Littel-van den Hurk, S. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 2012, 30, 5206-5214.
107. Haining, W.N.; Anderson, D.G.; Little, S.R.; von Bergwelt-Baildon, M.S.; Cardoso, A.A.; Alves, P.; Kosmatopoulos, K.; Nadler, L.M.; Langer, R.; Kohane, D.S. pH-triggered microparticles for peptide vaccination. J. Immunol. 2004, 173, 2578-2585.
108. Seubert, A.; Calabro, S.; Santini, L.; Galli, B.; Genovese, A.; Valentini, S.; Aprea, S.; Colaprico, A.; D'Oro, U.; Giuliani, M.M.; et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl. Acad. Sci. USA 2011, 108, 11169-11174.
109. Calabro, S.; Tortoli, M.; Baudner, B.C.; Pacitto, A.; Cortese, M.; O'Hagan, D.T.; de Gregorio, E.; Seubert, A.; Wack, A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29, 1812-1823.
110. Dupuis, M.; McDonald, D.M.; Ott, G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 1999, 18, 434-439.
111. Didierlaurent, A.M.; Morel, S.; Lockman, L.; Giannini, S.L.; Bisteau, M.; Carlsen, H.; Kielland, A.; Vosters, O.; Vanderheyde, N.; Schiavetti, F.; et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 2009, 183, 6186-6197.
112. Baldrick, P.; Richardson, D.; Elliott, G.; Wheeler, A.W. Safety evaluation of monophosphoryl lipid A (MPL): An immunostimulatory adjuvant. Regul. Toxicol. Pharmacol. 2002, 35, 398-413.
113. Lawson, L.B.; Freytag, L.C.; Clements, J.D. Use of nanocarriers for transdermal vaccine delivery. Clin. Pharmacol. Ther. 2007, 82, 641-643.
114. Shima, F.; Akagi, T.; Akashi, M. The role of hydrophobicity in the disruption of erythrocyte membrane by nanoparticles composed of hydrophobically modified poly(gamma-glutamic acid). J. Biomater. Sci. Polym. Ed. 2014, 25, 203-210.
115. Yang, Y.; Neef, T.; Mittelholzer, C.; Garcia Garayoa, E.; Bläuenstein, P.; Schibli, R.; Aebi, U.; Burkhard, P. The biodistribution of self-assembling protein nanoparticles shows they are promising vaccine platforms. J. Nanobiotechnol. 2013, 11, doi:10.1186/1477-3155-11-36.
116. WHO Vaccine Standardization; Available online: http://www.who.int/biologicals/publications/ nonclinical_evaluation_vaccines_nov_2003.pdf (accessed on 11 April 2014).
117. Glenn, G.M.; Smith, G.; Fries, L.; Raghunandan, R.; Lu, H.; Zhou, B.; Thomas, D.N.; Hickman, S.P.; Kpamegan, E.; Boddapati, S.; et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31, 524-532.